Linked Life Data

9128847

Source:http://linkedlifedata.com/resource/pubmed/id/9128847

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2-3
pubmed:dateCreated
1997-6-16
pubmed:abstractText
Systemic administration of agents which elevate cyclic AMP (e.g., phosphodiesterase inhibitors, prostanoids, beta-adrenoceptor agonists) effectively modulates eosinophil recruitment in vivo. The present study was undertaken to evaluate whether the eosinophil itself is a cellular target for the inhibitory action of these drugs in vivo. We chose to use the long-acting beta 2-adrenoceptor agonist salmeterol to test this hypothesis. Eosinophils were pretreated with salmeterol (10(-6) M) before washing and testing in two salmeterol-sensitive systems, namely eosinophil aggregation and 111In-eosinophil accumulation in guinea-pig skin. Pretreatment with salmeterol inhibited by 65% and 43% eosinophil aggregation induced by platelet-activating factor (PAF) and human recombinant C5a, respectively. Similarly, 111In-eosinophil accumulation induced by PAF and zymosan-activated plasma, a source of guinea-pig des-Arg-C5a, was inhibited by 55% and 45%, respectively. In contrast, the level of circulating 111In-eosinophils at 1 h was enhanced by 35% in animals which received salmeterol-pretreated 111In-eosinophils. Our results suggest that the eosinophil itself is one of the cellular targets of the inhibitory action of systemically administered salmeterol on eosinophil recruitment in vivo.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0014-2999
pubmed:author
pubmed:issnType
Print
pubmed:day
4
pubmed:volume
323
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
255-60
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Evidence that the eosinophil is a cellular target for the inhibitory action of salmeterol on eosinophil recruitment in vivo.
pubmed:affiliation
Imperial College of Medicine at the National Heart and Lung Institute, London, UK. mauro.teixeira@ic.ac.uk
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't